Pinned Tweet
The focused update of the KDIGO 2027 CKD Guideline is available for public review through November 4, 2026.
KDIGO invites the global kidney community to review the draft and share feedback to help inform and improve the final update.
Visit the KDIGO CKD Guideline website to download the draft and share your comments via the feedback survey:
kdigo.org/guidelines/ckd-eva…
The focused update addresses new evidence since publication of the KDIGO 2024 CKD Guideline on SGLT2 inhibitors, GLP-1-based therapies, and nsMRAs in people with CKD, excluding those receiving dialysis or who have received a kidney transplant.
Thank you for your time and insights.
We are pleased to share the newest episode of the KDIGO Conversations in Nephrology podcast!
In Episode 35, the second in KDIGO’s latest three-part series on IgAN, Dr. Brad Rovin is joined by Dr. Andrew Bomback to explore which patients may benefit from complement inhibition and what information could help guide treatment selection.
Listen now on your favorite podcast platform: kdigo.co/Convos-in-Nephrolog…
The discussion examines kidney biopsy findings, genetic testing, and emerging complement biomarkers, as well as practical lessons from treating C3 glomerulopathy, including vaccination, antibiotic prophylaxis, and multidisciplinary care.
There is still time to share your feedback! The focused update of the KDIGO 2027 CKD Guideline is available for public review through November 4, 2026.
Visit the KDIGO CKD Guideline website to download the draft and share your comments via the feedback survey: kdigo.org/guidelines/ckd-eva…
The focused update addresses new evidence since publication of the KDIGO 2024 CKD Guideline on SGLT2 inhibitors, GLP-1-based therapies, and nsMRAs in people with CKD, excluding those receiving dialysis or who have received a kidney transplant.
ALT KDIGO 2027 CKD Guideline Public Review Draft
Check out the latest issue of KDIGO Direct for news and updates from KDIGO: kdigo.co/KDIGO-Direct-Oct-20…
In this issue:
• Learn about KDIGO guideline methodology in a new series in @Kidney_Int
• Share feedback on the draft KDIGO 2027 CKD Guideline Update out for public review through November 4
• Take part in a new survey on C3G and aHUS
• Listen to the new IgAN episode of the KDIGO Conversations in Nephrology podcast
• Learn about upcoming KDIGO activities and events
• Explore new educational resources
Attending #KidneyWk? Don't miss the Exhibitor Spotlight on the forthcoming KDIGO AKI/AKD Guideline.
Thursday, October 22, 11:30 AM - 12:15 PM MDT
Theater 2, Exhibit Hall A, Colorado Convention Center
Hear from KDIGO AKI/AKD Guideline Co-Chair Dr. Marlies Ostermann, Work Group Member Dr. Jay Koyner, and Dr. Pedro Teixeira as they explore key areas addressed in the proposed guidance, including AKI diagnosis, medical management, and considerations for kidney replacement therapy.
No advance registration or assigned seating is required. Arrive early for the best seats.
KDIGO retweeted
IPNA Commentary on the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD
@IPNA_PedNeph @goKDIGO @LittleKidneys @ESPNSociety
link.springer.com/article/10… – at Naval Base Kitsap, WA
KDIGO retweeted
IgA Nephropathy #IgAN: Pathophysiology and Mechanistic Targets 🎯 of Potential Novel Therapies from @goKDIGO
#Nephpearls
👉 kdigo.org/infographics/
KDIGO retweeted
C3G Glomerulopathy: Mechanistic Targets 🎯 of Potential Novel Therapies from @goKDIGO
#Nephpearls
👉 kdigo.org/infographics/ – at Riverside, IL
Are you attending #EASD2026? Don't miss the KDIGO session on Thursday, 1 October, from 12:30 - 14:00 in Berlin Hall at the Milan Convention Centre.
“Matters Arising for Kidney and Diabetes: What's New from KDIGO” will highlight current and forthcoming KDIGO work addressing the interconnected challenges of diabetes, kidney disease, and cardiovascular health.
Please stop by and say hello at the KDIGO booth (#32) in the EASD Community Plaza!
KDIGO retweeted
Targeting B cells in immune-mediated kidney diseases: conclusions from @goKDIGO Controversies Conference ca. 2026
#Nephpearls #RKDSummit
👉🏼 pubmed.ncbi.nlm.nih.gov/4203…
KDIGO retweeted
🌏✨ Day 4 at @ttsorg 2026 — Science, People & Impact 🇦🇺
What a wonderful way to close an incredible 31st International Congress of #TheTransplantationSociety in Sydney !
🎤 Honored to speak in one of the closing sessions, “#LivingOrganDonation in 2026: Unified Principles, Organ-Specific Nuances,” sharing perspectives on a medical, psychosocial, and ethical framework for living donor evaluation.
🙏🏽 Many thanks to our chairs Kwang Woong Lee ➕ Henry Pleass, and to fellow speakers Mireia Musquera, Dong Jin Joo ➕ Allan Massie for an engaging discussion spanning living kidney and liver donation, surgical outcomes, predictive models, and donor safety.
🤝🏽 And, as throughout #TTS2026, some of the most valuable moments happened beyond the podium — catching up with longtime friends, meeting new colleagues, exchanging ideas, and finding new opportunities to collaborate.
📘 A highlight from TTS was hearing an overview of the @goKDIGO #KidneyTransplant Recipient Guideline update and connecting with @germjacq | @MichelleJTx | Tanya Green ➕ More around this important international effort. 💚💙 🤝🏽
💫 Four remarkable days of science, collaboration, friendship, and shared commitment to advancing transplantation worldwide. KAPIL GOTHWAL | @drvivekkute | @DrDEMartin | Hatem Amer | @LVRiella | @mannonmom | @SSMHealthSTL | @SSMHealth | @slusom 🏥🤲🏽
📸 A few moments from Day 4 — final Sydney wrap-up still to come!
#TTS2026 #Transplantation #LivingDonation #LivingKidneyDonation #KidneyTransplantation #DonorSafety #KDIGO #TransplantResearch #Sydney
KDIGO retweeted
❤️🩹 Do not overlook the diagnostic complexity of CVD in CKD.
Troponin and natriuretic peptides may be chronically elevated in CKD; interpretation requires clinical context, serial change and appropriate imaging, rather than isolated biomarker thresholds.
KDIGO retweeted
Experts debated controversies on the role of #complement in #kidneydisease - better patient outcomes start with the latest clinical & research advancements. @goKDIGO ahusallianceaction.org/the-k…
Share #aHUS info & insights using #aHUS24Sept to highlight aHUS Awareness Day!
KDIGO is pleased to be in Belo Horizonte for the Brazilian Congress of Nephrology (CBN) 2026.
Today’s plenary featured @pecoitsfilho discussing “From Evidence to Action: Practical Aspects of Guideline Implementation” and Dr. @vjha126 presenting “KDIGO Perspectives in IgA Nephropathy: Global Insights.”
Thank you to Otsuka for its support and to the Brazilian Society of Nephrology for the warm welcome.
KDIGO retweeted
Updated guidance from @goKDIGO recommends a more individualized approach to managing anemia in chronic kidney disease, including tailored treatment decisions, preferred use of IV iron for patients on hemodialysis, and addressing reversible causes before drug therapy. Read a synopsis of the guidelines here: bit.ly/4yhoVDn
KDIGO retweeted
#KDOQI US Commentary on the @goKDIGO 2026 Clinical Practice Guideline for the Management of Anemia in CKD
bit.ly/KDOQI26Anemia (FREE)
@NishaKidneyDoc @ogutierrez136 @NKF_NephPros
Check out the latest issue of KDIGO Direct for news and updates from KDIGO: kdigo.co/KDIGO-Direct-Septem…
In this issue:
• New KDIGO publications on IgAN, B-Cell Therapies, and CKM in the September issue of @Kidney_Int
• KDIGO ECP article on kidney paired exchange in Germany in @KIReports
• KDIGO at the Brazilian Congress of Nephrology, #TTS2026, and #EASD2026
• KDIGO IgAN updates from @GlomCon Hawaii 2026
• New KDIGO FSGS podcast series
• New educational activities on anemia, IgAN, C3G, and IC-MPGN
KDIGO retweeted
⏳🚨 A quick summary of the latest IgAN developments by @VladoPerkovic
@goKDIGO updates from glomcon Hawaii 2026
youtu.be/GMsK31N0T3U?si=5-ot…
